The impact of compound Danshen dropping pills on ventricular remodeling and cardiac function after acute anterior wall myocardial infarction: a multicenter, randomized, double-blind, placebo-controlled clinical trial

Phase 4

Recruiting

• Conditions: Acute anterior wall myocardial infarction

• Registration Number: ITMCTR2000003341
• Lead Sponsor: The First Affiliated Hospital of Nanjing Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Aged 18-75 years, gender unlimited;
2. According to the guidelines for diagnosis and treatment of acute ST segment elevation myocardial infarction (2019), patients with acute anterior ST segment elevation myocardial infarction were diagnosed;
3. Patients with primary acute myocardial infarction;
4. Patients who completed PCI reperfusion treatment within 12 hours after the onset of the disease;
5. Patients with Killip grading between I and III;
6. Subjects participated in the study voluntarily and signed informed consent.

Exclusion Criteria

1. Patients with previous cardiac insufficiency caused by other diseases (valvular heart disease, congenital heart disease, pericardial disease, arrhythmia, other non cardiac causes);
2. The patients underwent CABG within 12 weeks;
3. Patients undergoing cardiac resynchronization;
4. Patients with left ventricular outflow tract obstruction;
5. Patients with myocarditis;
6. Patients with uncontrolled severe arrhythmia;
7. Patients with aortic aneurysm;
8. Patients with serious liver, kidney, blood system, mental disease or systemic disease;
9. Significant liver and kidney dysfunction (ALT > 2.0 times the upper limit of normal value; creatinine > 1.5 times the upper limit of normal value);
10. Patients with serum potassium > 5.5mmol/l;
11. Uncontrolled hypertension (higher than 180 / 110mmhg);
12. Pregnant or lactating women;
13. Patients allergic to compound Danshen Dropping Pills;
14. Patients participating in clinical studies of other drugs.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ultrasonic cardiogram;

Secondary Outcome Measures

Name	Time	Method
cardiac arrhythmia;NT-proBNP decline level;Adverse cardiovascular events;